12 December 2025 - The EMA’s CHMP recommended seven medicines for approval at its December 2025 meeting.

The committee recommended granting a conditional marketing authorisation for Anktiva (nogapendekin alfa inbakicept), for the treatment of adults with a type of bladder cancer that affects the lining of the bladder (non-muscle invasive bladder cancer) and that is at high risk of growing and spreading.

Read EMA press release